A Nature Communications study reports that the B-cell marker CD19 can be transferred between immune cells in both mice and humans, adding a new mechanism for how surface proteins move across the immune microenvironment. The findings suggest CD19 dynamics may complicate interpretation of cellular phenotypes and could influence immune interactions relevant to B-cell malignancies and immunotherapies. The study builds on observations that immune cell-to-cell contact can support protein exchange. By showing CD19 transfer is not limited to a mouse model, the authors extend the concept into human biology and support continued investigation into how transferred markers affect signaling and functional states. For translational immuno-oncology, the result matters because therapeutic responses often rely on marker-defined cell populations. Better understanding of marker transfer may improve patient stratification, biomarker design, and the interpretation of flow and imaging assays used in trials.